An interventional study of Botulinum toxin type A injection in Freezing of Gate, Parkinson Disease and Botulinum Toxin, sponsored by Centro Hospitalar de Lisboa Central. Not yet recruiting at 1 site in Portugal. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Centro Hospitalar de Lisboa Central · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Parkinson Disease with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Parkinson Disease · Portugal.
Among the 55 studies in Parkinson Disease with a site in Portugal, this one is the 41st largest by planned enrollment of the 51 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 51st registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 55 studies in Parkinson Disease with a site in Portugal are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Portugal, United States, Australia and 14 more countries
Ages 50–85
University of Coimbra · Sites in Portugal
Ages 21–65
Albino Maia · Sites in Portugal
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 9 · Phase 3 16 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 106 across the 51 interventional studies, 684 across the 3 observational. Of the 47 that completed or were terminated, 15 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 55 have an industry lead sponsor. The 10 most frequent:
Centro Hospitalar de Lisboa Central is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Centro Hospitalar de Lisboa Central has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 55 studies in Parkinson Disease with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Freezing of gait is a symptom of Parkinson's disease (PD) that becomes more evident with the evolution of the disease, and which presents an important difference compared to the other signs and symptoms: does not respond adequately to dopaminergic therapy, which calls into question its pathophysiology. In this sense, and through empirical experience, it has been noted that freezing responds to cueing techniques (visual, sensory motor, auditory tricks, among others) which suggests a similarity with dystonic pathology. This similarity could be the basis of a common response to botulinum toxin (BT). Objectives: This study aims to understand whether BT is an effective therapy for freezing gait in patients with Parkinson's disease. Methodology: This is a prospective parallel study with therapeutic intervention, controlled by placebo, double blind. The randomization of groups will be stratified. The population will be recruited from from the CHLC movement disorders consultation, and that meets the following inclusion criteria: Parkinson's disease with freezing of gait, scoring > 1 at point 2.13 on the scale MDS-UPDRS and be responsive to cueing techniques, with severity of Parkinson's disease rated 3 or 4 on the Hoehn \& Yahr scale. The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
Study with therapeutic intervention, placebo-controlled, double-blind, with stratified randomization using the minimization method. The variables to consider by this method will be binary variables and three will be considered: the severity of the freezing (degree 2 freezing / degree 3 and 4 freezing)8, the severity of the disease Parkinson's (Hoehn \& Yahr (H\&Y) stage 3 / H\&Y stage 4)9 and cognitive capacity (Mini-Mental State Examination (MMSE) 10-23 / MMSE 24-30)10.
People with Parkinson's disease in advanced stages, with freezing of gait frequent, responsive to cueing techniques, followed in consultation for diseases of the movement at CHULC, with the participation of doctors specializing in diseases of movement. All eligible participants will be required to complete the consent informed prior to their inclusion in the study.
Inclusion criteria: people with idiopathic Parkinson's disease with the presence of gait freezing, which scores > 1 at point 2.13 of the MDS-UPDRS8 scale and is responsive to cueing techniques, with severity of Parkinson's disease classified between 3 and 4 on the Hoehn \& Yahr9 scale.
Exclusion criteria: previous exposure to toxin therapy, alteration of therapy for PD during the course of the study, cognitive impairment with MMSE10 \< 10.
There will be two distinct modalities of observation and assessment of patients: in person, every month for 4 months, with observation of the patient and application of MDS-UPDRS8 scale, Timed Up \& Go (TUG) scale11, and Two Minutes Walk scale12 and telephone, every week for 4 months, with the application of a questionnaire on the freezing and another about the impression of improvement. Both assessment modalities will be carried out by doctors from the Neurology service.
Inclusion Criteria: people with idiopathic Parkinson's disease with the presence of gait freezing, which scores > 1 at point 2.13 of the MDS-UPDRS8 scale and is responsive to cueing techniques, with severity of Parkinson's disease classified between 3 and 4 on the Hoehn \& Yahr9 scale.
Exclusion Criteria: previous exposure to toxin therapy, alteration of therapy for PD during the course of the study, cognitive impairment with MMSE10 \< 10.
The botulinum toxin injection will be carried out by a doctor with experience in this therapeutic modality, which in turn is not part of the group of doctors who observe patients in the initial and subsequent phases. 100 Units (U) of botulinum toxin type A, in each lower limb (200 U in total), in muscle proximal thigh, once, at a moment that will be defined as T0. This group of 10 participans.
Drug: Botulinum toxin type A injection
In the control group, patients will be subject to the same protocol, with the difference in that the injections will be saline, although they look the same on the outside. You doctors carrying out therapy and evaluating progress during face-to-face visits will not have access to the distribution of groups. This group of 10 participans.
Drug: Botulinum toxin type A injection
The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
Variation Unified Parkinson's Disease Rating Scale (MDS-UPDRS8)
which is defined as fever (auricular temperature \>38ºC) and elevation of CRP (\> 75 mg/L), during the first 3 days after operation.
Time frame: for 4 months after the study
Variation Escala "Timed Up & Go"11
20% improvement in completion time in any reevaluations;
Time frame: for 4 months after the study
Variation Escala Two Minutes Walk12
20% improvement in the distance covered in any reevaluations;
Time frame: for 4 months after the study
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Jun 2024, 0 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 0 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Centro Hospitalar de Lisboa Central